Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 100.
78. lappuse
... obtain an in- vestigational drug subject to a con- trolled clinical trial for a treatment use , the practitioner should first at- tempt to obtain the drug from the sponsor of the controlled trial under a treatment protocol . If the ...
... obtain an in- vestigational drug subject to a con- trolled clinical trial for a treatment use , the practitioner should first at- tempt to obtain the drug from the sponsor of the controlled trial under a treatment protocol . If the ...
96. lappuse
... obtain the subject's freely - given informed consent , pref- erably in writing . 10. When obtaining informed consent for the research project the physician should be particularly cautious if the subject is in a dependent relationship to ...
... obtain the subject's freely - given informed consent , pref- erably in writing . 10. When obtaining informed consent for the research project the physician should be particularly cautious if the subject is in a dependent relationship to ...
130. lappuse
... obtain permission from FDA to submit such an abbreviated applica- tion . ( c ) To obtain permission to submit an abbreviated new drug application for a change described in paragraph ( b ) of this section , a person must submit and ...
... obtain permission from FDA to submit such an abbreviated applica- tion . ( c ) To obtain permission to submit an abbreviated new drug application for a change described in paragraph ( b ) of this section , a person must submit and ...
190. lappuse
... obtain treatment use of designated or- phan drugs may do so as provided in § 312.34 of this chapter . Subpart F - Availability of Information § 316.50 Guidelines . FDA's Office of Orphan Products De- velopment will maintain and make ...
... obtain treatment use of designated or- phan drugs may do so as provided in § 312.34 of this chapter . Subpart F - Availability of Information § 316.50 Guidelines . FDA's Office of Orphan Products De- velopment will maintain and make ...
289. lappuse
... obtain the re- view and approval of an institutional review committee that conforms to the requirements of part 56 of this chapter , and shall obtain the consent of the sub- jects or their legal representatives in accordance with part ...
... obtain the re- view and approval of an institutional review committee that conforms to the requirements of part 56 of this chapter , and shall obtain the consent of the sub- jects or their legal representatives in accordance with part ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning